Skip to main content
. Author manuscript; available in PMC: 2013 May 21.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2009 Jan 23;75(1):156–163. doi: 10.1016/j.ijrobp.2008.10.043

Figure 3.

Figure 3

The upper panel shows pre-treatment perfusion MRI studies and the lower panel shows the perfusion MRI studies after one cycle of bevacizumab for a left frontal lobe glioblastoma patient. There are increased ratios of transfer coefficient (Ktrans) (A), fractional blood volume (fBV) (B) and relative cerebral blood volume (rCBV) (C) before treatment; Ktrans (D), fBV (E) and rCBV (F) normalized after the first cycle of bevacizumab.

HHS Vulnerability Disclosure